Wang Zijing, Cai Ruopeng, Wang Gang, Guo Zhimin, Liu Xiao, Guan Yuan, Ji Yalu, Zhang Hao, Xi Hengyu, Zhao Rihong, Bi Lanting, Liu Shanshan, Yang Li, Feng Xin, Sun Changjiang, Lei Liancheng, Han Wenyu, Gu Jingmin
Key Laboratory of Zoonosis Research, Ministry of Education, College of Veterinary Medicine, Jilin University, Changchun, China.
College of Animal Science and Technology, Jilin Agricultural University, Changchun, China.
Front Microbiol. 2021 Apr 22;12:674068. doi: 10.3389/fmicb.2021.674068. eCollection 2021.
() is an important nosocomial and community acquired opportunistic pathogen which causes various infections. The emergence of multi-drug resistant (MDR) and carbapenem-resistant hypervirulent (CR-hvKP) has brought more severe challenge to the treatment of infection. In this study, a novel bacteriophage that specifically infects was isolated and named as vB_KpnM_P-KP2 (abbreviated as P-KP2). The biological characteristics of P-KP2 and the bioinformatics of its genome were analyzed, and then the therapeutic effect of P-KP2 was tested by animal experiments. P-KP2 presents high lysis efficiency . The genome of P-KP2 shows homology with nine phages which belong to "" family and its genome comprises 172,138 bp and 264 ORFs. Besides, P-KP2 was comparable to gentamicin in the treatment of lethal pneumonia caused by W-KP2 (K47 serotype). Furthermore, the combined treatment of P-KP2 and gentamicin completely rescued the infected mice. Therefore, this study not only introduces a new member to the phage therapeutic library, but also serves as a reference for other phage-antibiotic combinations to combat MDR pathogens.
（）是一种重要的医院获得性和社区获得性机会致病菌，可引起各种感染。多重耐药（MDR）和碳青霉烯耐药高毒力（CR-hvKP）的出现给感染治疗带来了更严峻的挑战。在本研究中，分离出一种特异性感染的新型噬菌体，并将其命名为vB_KpnM_P-KP2（简称为P-KP2）。分析了P-KP2的生物学特性及其基因组的生物信息学，然后通过动物实验测试了P-KP2的治疗效果。P-KP2具有较高的裂解效率。P-KP2的基因组与属于“”家族的9种噬菌体具有同源性，其基因组由172,138 bp和264个开放阅读框组成。此外，在治疗由W-KP2（K47血清型）引起的致死性肺炎方面，P-KP2与庆大霉素相当。此外，P-KP2和庆大霉素联合治疗完全挽救了感染小鼠。因此，本研究不仅为噬菌体治疗文库引入了一个新成员，也为其他噬菌体-抗生素联合治疗多重耐药病原体提供了参考。
